Lingrui Pharma(SH:600285)2023-04-25 16:00Financial Performance - Net profit attributable to shareholders increased by 10.30% to ¥144,246,384.90[5] - Net profit attributable to shareholders after deducting non-recurring gains and losses increased by 31.71% to ¥137,935,222.71, mainly due to an increase in operating income[6] - Operating revenue increased by 15.62% to ¥788,648,249.06[5] - Basic earnings per share rose by 9.70% to ¥0.260[5] - Diluted earnings per share increased by 10.92% to ¥0.254[5] - Net profit for the period reached ¥144,180,298.27, compared to ¥130,703,737.36 in the previous period, reflecting a growth of approximately 10.3%[28] - Total comprehensive income attributable to the parent company for Q1 2023 was ¥144,438,296.32, compared to ¥141,931,560.56 in Q1 2022, showing a slight increase of 3.6%[46] Assets and Liabilities - Total assets increased by 3.39% to ¥4,491,462,147.19 compared to the end of the previous year[2] - The company's total assets increased to ¥4,491,462,147.19 from ¥4,344,382,669.23, marking a rise of about 3.4%[27] - The equity attributable to shareholders of the parent company grew to ¥2,698,987,708.12, up from ¥2,550,918,961.13, which is an increase of approximately 5.8%[27] - The total liabilities as of Q1 2023 were ¥1,784,981,313.28, a slight decrease from ¥1,785,916,842.12 in Q1 2022[54] - The company recorded a total liability and equity of ¥4,491,462,147.19, consistent with the total assets, indicating a balanced financial position[27] Cash Flow - Net cash flow from operating activities decreased by 5.60% to ¥81,521,628.54[5] - Net cash generated from operating activities was ¥836,158,048.46 in Q1 2023, compared to ¥629,898,482.07 in Q1 2022, indicating a significant increase of 32.8%[57] - The net increase in cash and cash equivalents for Q1 2023 was ¥241,987,944.29, contrasting with a decrease of ¥47,538,320.80 in Q1 2022[49] - Operating cash inflow totaled CNY 873,767,046.56, an increase from CNY 668,624,954.82 in the previous period, reflecting a growth of approximately 30.7%[59] - Operating cash outflow amounted to CNY 792,245,418.02, compared to CNY 582,266,126.03, indicating an increase of about 36.0%[59] - Cash inflow from investment activities reached CNY 269,457,277.50, a decrease from CNY 280,069,462.48, showing a decline of approximately 2.2%[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,330[3] - The company repurchased and canceled 159,312 restricted stocks, adjusting the total number of granted restricted stocks to 13,211,288[23] Expenses - Total operating costs for Q1 2023 were ¥622,764,688.53, up 10.1% from ¥565,337,386.79 in Q1 2022[44] - Research and development expenses increased to ¥21,205,202.59 in Q1 2023, compared to ¥20,140,886.19 in Q1 2022, reflecting a growth of 5.3%[44] - Sales expenses for Q1 2023 amounted to ¥376,349,019.13, an increase of 14.5% from ¥328,590,129.99 in Q1 2022[44] - Cash paid to employees increased to CNY 77,976,112.17 from CNY 62,791,788.93, marking a rise of approximately 24.2%[59] - Taxes paid rose to CNY 146,557,715.10 from CNY 94,317,303.04, indicating an increase of around 55.4%[59] Other Financial Metrics - The weighted average return on equity decreased by 0.08 percentage points to 5.50%[2] - Interest income increased to ¥6,559,323.78 from ¥5,077,301.07, showing a growth of about 29.2%[28] - The company reported a financial expense of -¥5,819,501.33, compared to -¥3,642,842.09 in the previous period, indicating an increase in financial costs[28] - Other comprehensive income after tax for the period was ¥204,257.86, compared to ¥11,162,985.63 in the previous period, showing a significant decrease[28] - The company’s long-term equity investments remained stable at ¥71,690,947.15, slightly up from ¥71,652,345.36[26]